학술논문
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Document Type
Article
Author
Harrison, C.N.; Gupta, V.K.; Gerds, A.T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J.-J.; Mesa, R.; Kuykendall, A.T.; Vannucchi, A.M.; Palandri, F.; Grosicki, S.; Devos, T.; Jourdan, E.; Wondergem, M.J.; Al-Ali, H.K.; Buxhofer-Ausch, V.; Alvarez-Larrán, A.; Patriarca, A.; Kremyanskaya, M.; Mascarenhas, J.; Mead, A.J.; Akhani, S.; Sheikine, Y.; Colak, G.
Source
In: Future Oncology . (Future Oncology, 1 September 2022, 18(27):2987-2997)
Subject
Language
English
ISSN
17448301
14796694
14796694